Menactra Label Does Not Allow For Comparative Claims, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Sanofi-Aventis' Menactra does not allow for superiority claims, FDA said in its Jan. 14 approval letter for the meningococcal conjugate vaccine
You may also be interested in...
Sanofi-Aventis Eyes Expanded Menactra Indication Following Initial Approval
FDA approves the meningococcal conjugate vaccine for patients 11-55 years old; Sanofi-Aventis will submit a sBLA for use in children ages 2-11 by February. The company is currently studying the vaccine in patients under age 2 and will initiate a study evaluating Menactra in subjects over age 55 years by January 2006.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability